Medication use and multiple myeloma risk in Los Angeles County

Cancer Causes and Control

Volumn 25, Issue 9, 2014, Pages 1233-1237

  Nuyujukian, Daniel S ^a,b   Voutsinas, Jenna ^a   Bernstein, Leslie ^a   Wang, Sophia S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ERYTHROMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; CALIFORNIA; CASE CONTROL STUDY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; ERYTHROMYCIN; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; LOS ANGELES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; RISK FACTORS;

EID: 84939885001     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0424-0     Document Type: Article

References (25)

1. Palumbo A, Anderson K (2011) Medical progress multiple myeloma. N Engl J Med 364(11):1046–1060
2. Cancer Facts & Figures (2014) American Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed 6 March 2014
3. Becker N (2011) Epidemiology of multiple myeloma. Recent Results Cancer Res 183:25–35
4. Landgren O, Zhang YW, Zahm SH, Inskip P, Zheng TZ, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: a case–control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15(12):2342–2347
5. De Roos AJ, Baris D, Weiss NS, Herrinton LJ (2006) Multiple myeloma. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, Oxford
6. Selby JV, Friedman GD, Fireman BH (1989) Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 49(20):5736–5747
7. Linet MS, Harlow SD, McLaughlin JK (1987) A case–control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res 47(11):2978–2981
8. Eriksson M (1993) Rheumatoid arthritis as a risk factor for multiple myeloma: a case–control study. Eur J Cancer 29A(2):259–263
9. Wang SS, Voutsinas J, Chang ET, Clarke CA, Lu Y, Ma H, West D, Lacey JV Jr, Bernstein L (2013) Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis. Cancer Causes Control 24(7):1279–1289
10. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24(5):339–346
11. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9(4):310–322
12. Ogu CC, Maxa JL (2000) Drug interactions due to cytochrome P450. Proceedings (Bayl Univ Med Cent) 13(4):421–423
13. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68(1):82–91
14. Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76(2):215–228
15. National Toxicology Program (1988) NTP toxicology and carcinogenesis studies of erythromycin stearate (CAS No. 643-22-1) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 338:1–167
16. Burns KE, Goldthorpe MA, Porteus F, Browett P, Helsby NA (2014) CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemother Pharmacol 73:651–655
17. Singh G, Driever PH, Sander JW (2005) Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128(Pt 1):7–17
18. Matzner Y, Polliack Y (1978) Lymphoproliferative disorders in four patients receiving chronic diphenylhydantoin therapy: etiological correlation or chance association. Isr J Med Sci 14:865–869
19. Aymard JP, Lederlin P, Witz F, Colomb JN, Faure G, Guerci O, Herbeuval R (1981) Multiple myeloma after phenytoin therapy. Scand J Haematol 26:330–332
20. Friedman G (1986) Multiple myeloma: relation to propoxyphene and other drugs, radiation and occupation. Int J Epidemiol 15:424–426
21. Beutler E (1994) G6PD deficiency. Blood 84:3613–3636
22. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113(22):5412–5417
23. Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O (2011) Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica 97(6):854–858
24. Landgren O, Rapkin JS, Mellemkjaer L, Gridley G, Goldin LR, Engels EA (2006) Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica 91(12):1697–1700
25. Rasmussen MLH, Hjalgrim H, Mølgaard-Nielsen D, Wohlfahrt J, Melbye M (2012) Antibiotic use and risk of non-Hodgkin lymphomas. Int J Cancer 131(7):E1158–E1165